

Prof dr hab. Wojciech Jurczak

Lista ważniejszych publikacji (IF > 650, IC > 182, Hirsh 20) :

1. [The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.](#) **Jurczak W**, Długosz-Danecka M, Rivas Navarro F. *Future Oncol.* 2018 Oct 3. doi: 10.2217/fo-2018-0388. [Epub ahead of print]
2. [Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.](#) **Jurczak W**, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. *Br J Haematol.* 2018 Sep 7. doi: 10.1111/bjh.15573. [Epub ahead of print]
3. [Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.](#) Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, **Jurczak W**, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B. *Br J Haematol.* 2018 Aug 30. doi: 10.1111/bjh.15539. [Epub ahead of print]
4. [Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group \(PALG\) real-life analysis.](#) Długosz-Danecka M, **Jurczak W**, Łątka-Cabała E, Morawska M, Gawroński K, Wiśniewska A, Dudziński M, Wąsik-Szczepanek E, Chmielowska E, Łabędź A, Wdowiak K, Hus I. *Pol Arch Intern Med.* 2018 Aug 31;128(7-8):421-426. doi: 10.20452/pamw.4294. Epub 2018 Jul 11.
5. [Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.](#) Wróbel T, Biecek P, Rybka J, Szulgo A, Sorbotten N, Giza A, Tyczyńska A, Nowara E, Badora-Rybicka A, Adamowicz K, Kulikowski W, Kroll-Balcerzak R, Balcerzak A, Spychałowicz W, Kalinka-Warzocho E, Kumiega B, Drozd-Sokołowska J, Subocz E, Sałek A, Machaczka M, Hołojda J, Pogrzeba J, Dobrzyńska O, Chmielowska E, **Jurczak W**, Knopińska-Postuszny W, Leśniewski-Kmak K, Maciej Zaucha J. *Leuk Lymphoma.* 2018 Jul 6:1-8. doi: 10.1080/10428194.2018.1482539. [Epub ahead of print]
6. [\[Peripheral blood cell count and inflammation-based markers in chronic rhinosinusitis\].](#) Zagólski O, Stręk P, **Jurczak W**, Gorzedowski P. *HNO.* 2018 Jun 22. doi: 10.1007/s00106-018-0527-0. [Epub ahead of print] German.
7. [Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.](#) Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, **Jurczak W**, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. *J Clin Oncol.* 2018 May 31;JCO2017768853. doi: 10.1200/JCO.2017.76.8853. [Epub ahead of print]
8. [Use of acalabrutinib in patients with mantle cell lymphoma.](#) Awan FT, **Jurczak W**. *Expert Rev Hematol.* 2018 Jun;11(6):495-502. doi: 10.1080/17474086.2018.1473030. Epub 2018 May 14.

9. [Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.](#) Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, **Jurczak W**, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. *J Clin Oncol*. 2018 May 1;JCO2017766840. doi: 10.1200/JCO.2017.76.6840. [Epub ahead of print]
10. [Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.](#) Rule S, **Jurczak W**, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. *Leukemia*. 2018 Feb 2. doi: 10.1038/s41375-018-0023-2. [Epub ahead of print] No abstract available.
11. [Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.](#) **Jurczak W**, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. *Ann Oncol*. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.
12. [Prospective subgroup analyses of the randomized MCL-002 \(SPRINT\) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.](#) Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, **Jurczak W**, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trněný M; SPRINT Trial Investigators. *Br J Haematol*. 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.
13. [Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.](#) Connors JM, **Jurczak W**, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. *N Engl J Med*. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: *N Engl J Med*. 2018 Mar 1;378(9):878.
14. [Acalabrutinib in relapsed or refractory mantle cell lymphoma \(ACE-LY-004\): a single-arm, multicentre, phase 2 trial.](#) Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, **Jurczak W**. *Lancet*. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.
15. [Research on Biosimilars: pivotal trials and principles.](#) **Jurczak W**, Vulto AG, Amersdorffer J, Kim WS, Coiffier B. *Lancet Haematol*. 2017 Sep;4(9): e409-e410. doi: 10.1016/S2352-3026(17)30152-7.
16. [Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.](#) Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, **Jurczak WJ**, Flinn IW, Kahl BS, Martin P, Kim Y, Shrey S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. *Haematologica*. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15. No abstract available.

17. [Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.](#) **Jurczak W**, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J, Lechuga M, Casey M, Boni J, Giza A, Hess G. *Leuk Lymphoma*. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
18. [Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma \(ASSIST-FL\): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.](#) **Jurczak W**, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zube A, Harlin O, Amersdorffer J. *Lancet Haematol*. 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.
19. [Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.](#) Kim WS, Buske C, Ogura M, **Jurczak W**, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. *Lancet Haematol*. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.
20. [Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.](#) Hess G, Rule S, **Jurczak W**, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M, Bence-Bruckler I, Cho SG, Zhou W, Goldberg JD, Trambitas C, Enny C, Vermeulen J, Traina S, Chiou CF, Diels J, Dreyling M. *Leuk Lymphoma*. 2017 Dec;58(12):2824-2832. doi: 10.1080/10428194.2017.1326034. Epub 2017 May 30.
21. [Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.](#) Szmit S, **Jurczak W**, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, Joks M, Drozd-Sokołowska J, Knopińska-Postuszny W, Spychałowicz W, Kumiega B, Charliński G, Morawska M, Słomian G. *Int J Cardiol*. 2017 May 15;235:147-153. doi: 10.1016/j.ijcard.2017.02.073. Epub 2017 Feb 22.
22. [Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.](#) Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, **Jurczak W**, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. *Lancet Oncol*. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.
23. [Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.](#) Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, **Jurczak W**, Flinn IW, Kahl BS, Martin P, Kim Y, Shrey S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. *Haematologica*. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15
24. [Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.](#) Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, **Jurczak W**, Galazka K, Długosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R, Sander B,

Pan-Hammarström Q. *Oncotarget*. 2016 Jun 21;7(25):38180-38190. doi: 10.18632/oncotarget.9500.

25. [Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy](#). Kocurek A, Małkowski B, Giza A, **Jurczak W**. *Contemp Oncol (Pozn)*. 2016;20(4):297-301. doi: 10.5114/wo.2016.61849. Epub 2016 Sep 5.
26. [Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report](#). **Jurczak W**, Bryk AH, Mensah P, Gałązka K, Trofimiuk-Müldner M, Wyrobek Ł, Sawiec A, Skotnicki AB. *J Med Case Rep*. 2016 May 14;10(1):123. doi: 10.1186/s13256-016-0875-x.
27. [Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study](#). Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, **Jurczak W**, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. *Lancet Oncol*. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
28. [Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma \(MCL-002; SPRINT\): a phase 2, randomised, multicentre trial](#). Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, **Jurczak W**, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. *Lancet Oncol*. 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.
29. [Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience](#). Rybka J, **Jurczak W**, Giza A, Paszkiewicz-Kozik E, Kumiega B, Drozd-Sokołowska J, Butrym A, Kuliczowski K, Wróbel T. *Adv Clin Exp Med*. 2015 Sep-Oct;24(5):783-9. doi: 10.17219/acem/34795
30. [Postibrutinib outcomes in patients with mantle cell lymphoma](#). Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Ibarri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, **Jurczak W**, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. *Blood*. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
31. [Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study](#). Dreyling M, **Jurczak W**, Jerkeman M, Silva RS, Rusconi C, Trněný M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. *Lancet*. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Erratum in: *Lancet*. 2016 Feb 20;387(10020):750.
32. [Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study](#). **Jurczak W**, Kalinka-Warzocha E, Chmielowska E, Duchnowska R, Wojciechowska-Lampka E, Wieruszewska K. *Contemp Oncol (Pozn)*. 2015;19(3):214-9. doi: 10.5114/wo.2015.52657. Epub 2015 Jul 8.

33. [Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.](#) **Jurczak W**, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Postuszny W, Stella-Hołowiecka B, Walewski J, Joks M, Wróbel T, Zaucha JM. *Pol Arch Med Wewn.* 2015;125(10):741-8. Epub 2015 Sep 3.
34. [The use of Yttrium-90 Ibritumomab Tiuxetan \(\(90\)Y-IT\) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.](#) **Jurczak W**, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Postuszny W, Khan O. *Contemp Oncol (Pozn).* 2015;19(1):43-7. doi: 10.5114/wo.2015.50012. Epub 2015 Mar 26.
35. [Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF \(CLN-19\) Study.](#) O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, **Jurczak W**, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. *J Clin Oncol.* 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.
36. [Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.](#) Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jędrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. *Blood.* 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9.
37. [Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.](#) **Jurczak W**, Kroll-Balcerzak R, Giebel S, Machaczka M, Giza A, Ogórka T, Fornagiel S, Rybka J, Wróbel T, Kumiega B, Skotnicki AB, Komarnicki M. *Med Oncol.* 2015 Apr;32(4):90. doi: 10.1007/s12032-015-0520-3. Epub 2015 Feb 26.
38. [Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following \(R\)-CHOP chemotherapy in patients with lymphoma.](#) Szmit S, **Jurczak W**, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, Długosz-Danecka M, Torbicki A. *J Am Soc Hypertens.* 2014 Nov;8(11):791-9. doi: 10.1016/j.jash.2014.08.009. Epub 2014 Aug 19.
39. [Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.](#) Krawczyk K, **Jurczak W**, Gałązka K, Gruchała A, Skotnicki AB. *J Med Case Rep.* 2014 Oct 2;8:325. doi: 10.1186/1752-1947-8-325.
40. [Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.](#) Sokolowska-Wojdyło M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, **Jurczak W**. *Am J Ther.* 2016 May-Jun;23(3):e749-56. doi: 10.1097/MJT.000000000000056.
41. [PI3K \$\delta\$ inhibition by idelalisib in patients with relapsed indolent lymphoma.](#) Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, **Jurczak W**, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. *N Engl J Med.* 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.

42. [Premature cardiovascular mortality in lymphoma patients treated with \(R\)-CHOP regimen - a national multicenter study.](#) **Jurczak W**, Szmit S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, Dziętczenia J, Wróbel T, Kumiega B, Zaucha JM, Knopińska-Postuszny W, Spychałowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB. *Int J Cardiol.* 2013 Oct 15;168(6):5212-7. doi: 10.1016/j.ijcard.2013.08.033. Epub 2013 Aug 15.
43. [\[Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggressive lymphomas\].](#) Kumiega B, **Jurczak W**, Fornagiel S, Dziętczenia J, Skotnicki AB. *Przegl Lek.* 2013;70(4):187-90. Polish.
44. [Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas.](#) Krawczyk K, **Jurczak W**, Długosz-Danecka M, Zauska-Giza A, Dziętczenia J, Wróbel T, Skotnicki AB. *Pol Arch Med Wewn.* 2013;123(11):589-95. Epub 2013 Sep 24.
45. [Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.](#) Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. *N Engl J Med.* 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
46. [Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.](#) Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, **Jurczak W**, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network. *Ann Oncol.* 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24.
47. [A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease.](#) Machaczka M, Arce MP, Rucinska M, Yoshitake T, Kehr J, **Jurczak W**, Skotnicki AB, Månsson JE, Tylki-Szymanska A, Svenningsson P. *JIMD Rep.* 2012;3:53-7. doi: 10.1007/8904_2011_48. Epub 2011 Sep 20.
48. [\[Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma\].](#) **Jurczak W**, Krochmalczyk D, Giza A, Sobociński M, Skotnicki AB. *Przegl Lek.* 2012;69(5):171-5. Polish.
49. [\[Hematological toxicity of radioimmunotherapy with 90Y Ibritumomab\].](#) **Jurczak W**, Szostek M, Jakóbczyk M, Staszczak AS, Zimowska-Curyło D, Giza A, Sobociński M, Hubalewska-Dydejczyk A, Skotnicki AB. *Przegl Lek.* 2012;69(3):107-14. Polish.
50. [Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.](#) Machaczka M, Wahlin BE, Piatkowska-Jakubas B, Rucinska M, **Jurczak W**, Balana-Nowak A, Klimkowska M, Hägglund H, Skotnicki AB. *Med Oncol.* 2012 Sep;29(3):2070-6. doi: 10.1007/s12032-011-0044-4. Epub 2011 Aug 23.
51. [Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network.](#) Hohloch K., Delaloye A. B., Windemuth-Kieselbach C., Gomez-Codina J., Linkesch W., **Jurczak W**., Cacchione R., Suh C., Zinzani P. L. i Trumper L. *Nucl Med.* 2011 Sep;52(9):1354-60. doi: 10.2967/jnumed.111.089920. Epub 2011 Aug 9.

52. [\[Post transplant lymphoproliferative disorder \(PTLD\)--10 years follow-up\]](#). Ignacak E, Betkowska-Prokop A, Kuźniewski M, Rudzki Z, Okoń K, Skotnicki A, **Jurczak W**, Kulig J, Czupryna A, Bucki J, Sułowicz W. *Przegl Lek*. 2011;68(12):1202-3. Polish.
53. [Radioimmunotherapy with \(90\)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network](#). Hohloch K, Zinzani PL, Linkesch W, **Jurczak W**, Deptala A, Lorsbach M, Windemuth-Kiesselbach C, Wulf GG, Truemper LH. *Bone Marrow Transplant*. 2011 Jun;46(6):901-3. doi: 10.1038/bmt.2010.202. Epub 2010 Sep 27. No abstract available.
54. [Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma \(MCL\): minutes of the 9th European MCL Network conference](#). Dreyling M, Hoster E, Bea S, Hartmann E, Horn H, Hutter G, Salaverria I, Pott C, Trneny M, Le Gouill S, Cortelazzo S, Szymczyk M, **Jurczak W**, Shpilberg O, Ribrag V, Hermine O; European MCL Network. *Leuk Lymphoma*. 2010 Sep;51(9):1612-22. doi: 10.3109/10428194.2010.496507. Review.
55. [New forms of radionuclide therapy with \(90\)Y in oncology](#). Hubalewska-Dydejczyk A, **Jurczak W**, Sowa-Staszczak A, Kunikowska J, Królicki L, Gilis-Januszewska A, Giza A, Szurkowska M, Pach D, Głowa B, Mikołajczak R, Pawlak D, Stefańska A, Huszno B, Skotnicki AB. *Nucl Med Rev Cent East Eur*. 2008;11(1):5-11.
56. [Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms](#). **Jurczak W**, Hubalewska-Dydejczyk A, Giza A, Sowa-Staszczak A, Huszno B, Skotnicki AB. *Nucl Med Rev Cent East Eur*. 2007;10(2):110-5. Review..
57. [Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's \(PLRG\) experience](#). **Jurczak W**, Hubalewska-Dydejczyk A, Giza A, Sowa-Staszczak A, Wróbel T, Mazur G, Boguradzki P, Knopińska-Postłuszny W, Huszno B, Skotnicki AB. *Nucl Med Rev Cent East Eur*. 2007;10(2):91-7.
58. [Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop](#). Zinzani PL, d'Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T, **Jurczak W**, Linkesch W, Morschhauser F, Vandenberghe E, Van Hoof A. *Eur J Cancer*. 2008 Feb;44(3):366-73. doi: 10.1016/j.ejca.2007.12.008. Epub 2008 Jan 14.
59. [Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: analysis of prognostic factors and comparison with a single procedure](#). Czyz J, Dziadziuszko R, Knopinska-Postłuszny W, Hellmann A, Kachel L, Hołowiecki J, Czyz A, Komarnicki M, Osowiecki M, Walewski J, **Jurczak W**, Skotnicki A; Polish Lymphoma Research Group. *Leuk Lymphoma*. 2007 Mar;48(3):535-41.
60. [\[Primary adrenal lymphoma in incidentally discovered adrenal tumour\]](#). Przybylik-Mazurek E, Darczuk A, Huszno B, Budzyński A, Rembiasz K, Gałazka K, Wierzchowski W, Giza A, **Jurczak W**, Skotnicki AB, Sztuk S, Urbanik A. *Przegl Lek*. 2006;63(8):701-5. Polish.
61. [\[New trends in non-Hodgkin's lymphoma therapy\]](#). Mazur G, Wróbel T, **Jurczak W**, Butrym A. *Postepy Hig Med Dosw (Online)*. 2006;60:707-21. Review. Polish..

62. [High prevalence of non-Hodgkin's lymphomas in Polish population--1106 new cases diagnosed according to WHO classification in only one district.](#) **Jurczak W**, Rudzki Z, Gałazka K, Gruchała A, Jaszcz-Gruchała A, Skotnicki AB, Stachura J. *Pol J Pathol.* 2006;57(1):45-52.
63. [ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.](#) Rudzki Z, Rucińska M, **Jurczak W**, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczek M, Włodarska I, Stachura J. *Pol J Pathol.* 2005;56(1):37-45. Review.
64. [Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.](#) Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Hołowiecki J, Goździk J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, **Jurczak W**, Skotnicki A, Sedzimirska M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszyńska A, Kus A, Robak T, Warzocha K. *Ann Oncol.* 2004 Aug;15(8):1222-30.
65. [\[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group\].](#) Hołowiecki J, Giebel S, Walewski J, Krawczyk-Kuliś M, Hellmann A, Skotnicki A, Dmoszyńska A, Romejko J, Czyz J, **Jurczak W**, Kachel Ł, Wojnar J, Stella-Hołowiecka B, Saduś-Wojciechowska M, Sułek K, Jedrzejczak W, Robak T, Mariańska B, Szczylik C, Warzocha K. *Pol Arch Med Wewn.* 2003 Aug;110(2):863-8. Polish.
66. [High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.](#) Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Goździk J, Hołowiecki J, Stella-Hołowiecka B, Kachel Ł, Knopińska-Postuszny W, Nagler A, Meder J, Walewski J, Lampka E, Sułek K, Sawicki W, Lange A, Forgacz K, Suchnicki K, Pacuszko T, Skotnicki A, Mensah P, **Jurczak W**, Kuliczowski K, Wróbel T, Mazur G, Dmoszyńska A, Wach M, Robak T, Warzocha K. *Bone Marrow Transplant.* 2002 Jul;30(1):29-34..
67. [\[Hodgkin's disease--diagnostic basis and therapy in light of randomized clinical trials\].](#) **Jurczak W**, Nowak WS, Mensah P, Skotnicki AB. *Przegl Lek.* 1999;56 Suppl 1:90-100. Review. Polish.
68. [\[Non Hodgkin's lymphoma--treatment of choice and the role of high dose chemotherapy\].](#) **Jurczak W**, Nowak W, Wójcik M, Skotnicki A. *Przegl Lek.* 1999;56 Suppl 1:80-9. Review. Polish.
69. [\[Diagnostics, classification and high dose chemotherapy in non Hodgkin's and Hodgkin's lymphoma\].](#) Nowak WS, **Jurczak W**, Wójcik M, Skotnicki AB. *Przegl Lek.* 1999;56 Suppl 1:73-9. Review. Polish.
70. [\[Harvesting bone marrow from the posterior superior iliac crest for transplantation\].](#) Sacha T, Zawirska D, **Jurczak W**, Hawrylecka D, Skotnicki AB. *Przegl Lek.* 1999;56 Suppl 1:40-3. Review. Polish.
71. [Parkinson's syndrome preceding clinical manifestation of Gaucher's disease.](#) Machaczka M, Rucinska M, Skotnicki AB, **Jurczak W**. *Am J Hematol.* 1999 Jul;61(3):216-7. No abstract available.

72. [\[All-trans-retinoic acid in the differential therapy of proliferative hemocytic diseases. I. Properties of biological retinoids\]](#). Skotnicki AB, Sledziowski P, Sacha T, **Jurczak W**. Przegł Lek. 1995;52(1):31-4. Review. Polish. No abstract available.\
73. [\[All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice\]](#). Skotnicki AB, Sledziowski P, Sacha T, **Jurczak W**. Przegł Lek. 1995;52(4):145-6. Review. Polish. No abstract available.
74. [\[Subendocardial blood flow index in relation to selected parameters of left-ventricular function in patients with aortic valve stenosis\]](#). Dubiel JS, Petkow-Dimitrow P, Reichhart J, **Jurczak W**, Zmudka K. Przegł Lek. 1992;49(3):73-5. Polish.
75. [\[Immunotoxic effect of asbestos\]](#). Lisiewicz J, **Jurczak W**. Przegł Lek. 1992;49(12):406-8. Review. Polish. No abstract available. [A preliminary assessment of the incidence of atopy at a workplace in Cracow]. Jurczak W, Rysz A, Kopiński P, Podolec Z, Głuszko P. Pol Tyg Lek. 1990 Oct 15-29;45(42-44):873-5. Polish.